ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
alxo · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$4.00
+154.8% upside
Low
$4.00
Median: $4 · Last Close: $1.57
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.49 | ↓ 5.00% |
1-day model range: $1.46–$1.52. Peak: $1.52 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ALXO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-05 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-05-21 | UBS | Maintains | Buy→Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-07 | Stifel | Maintains | Hold→Hold |
| 2025-03-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-06 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-03-06 | Jefferies | Upgrade ↑ | Hold→Buy |
| 2025-01-27 | UBS | Maintains | Buy→Buy |
| 2025-01-24 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on ALX Oncology Holdings Inc. (ALXO) stock. Of the recent 54 rating actions, 2 were upgrades and 3 were downgrades. 7 analysts currently cover ALXO.
Analyst Recommendation Trends
ALXO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$5M
↓ 91.6% YoY
Revenue Next Year
$5M
↑ 16.3% YoY
EPS This Year
$-0.61
EPS Next Year
$-0.58
↓ 5.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast ALXO EPS of $-0.61 for the current fiscal year, based on estimates from 3 analysts. The ALXO revenue forecast is $5M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ALXO stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ALXO price target is $4.00 (+154.8% upside), with an analyst consensus of Buy.
The ALXO short-term stock prediction for tomorrow is $1.49 (-5.00%).
ALX Oncology Holdings Inc. trades on NASDAQ under the ticker ALXO. The ALXO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
ALXO forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month ALXO price target is $4.00, with a high forecast of $4.00 and a low of $4.00. The median price target is shown in the chart above when available. This implies +154.8% potential upside from the current price of $1.57.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.